Your browser doesn't support javascript.
loading
A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel.
Wu, Yi-Long; Wang, Chang-Li; Sun, Yan; Liao, Mei-Lin; Guan, Zhong-Zhen; Yang, Zhi-Min; Zhou, Qing-Hua; Lu, Shun; Cheng, Ying; Liu, Xiao-Qing; Zhang, Xu-Chao; Zhou, Caicun; Wang, Jie; Zhou, Qing; Song, Yong; Han, Bao-Hui; Ma, Zhi-Yong; Yang, Fan; Wang, Qun; Chuai, Shao-Kun; Shao, Yang; He, Wei; Zhu, Guanshan; Xiong, Lei; Wang, Jian-Jun; Chen, Ke-Neng; Zhang, Li; Mao, Wei-Min; Ma, Sheng-Lin; Feng, Ji-Feng; Yang, Xue-Ning; Xu, Lin; Chen, Gang; Zhao, Jian; Song, Qi-Bin; Shen-Tu, Yang; Qiao, Gui-Bin; Yu, Ding; Yu, Shi-Ying; Hu, Yi; Chen, Ming; Chen, Gong-Yan; Fan, Yun; Zhang, He-Long; Liang, Jun; Zhu, Guang-Ying; Cui, Jiu-Wei; Yang, Jin-Ji; Zhao, Qiong; Zhao, Ming-Fang.
Afiliação
  • Wu YL; Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China. Electronic address: syylwu@gmail.com.
  • Wang CL; Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • Sun Y; National GCP Center for Anticancer Agents, National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Liao ML; Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
  • Guan ZZ; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Yang ZM; The Center for Drug Evaluation, China Food and Drug Administration, Beijing, China.
  • Zhou QH; Lung Cancer Center, West China Hospital, Chengdu, China.
  • Lu S; Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
  • Cheng Y; Department of Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun, China.
  • Liu XQ; Department of Pulmonary Oncology, 307 Hospital of the Academy of Military Medical Sciences, Beijing, China.
  • Zhang XC; Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Zhou C; Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China.
  • Wang J; Department of Medical Oncology, National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Zhou Q; Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Song Y; Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
  • Han BH; Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
  • Ma ZY; Department of Medical Oncology, Henan Cancer hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
  • Yang F; Department of Thoracic Surgery, Peking University People Hospital, Beijing, China.
  • Wang Q; Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Chuai SK; Burning Rock Biotech, Guangzhou, China.
  • Shao Y; Geneseeq Technology Inc, Nanjing, China; College of Basic Medicine, Nanjing Medical University, Nanjing, China.
  • He W; Geno Biotech Co Ltd, Shanghai, China.
  • Zhu G; R&D department, Amoy Diagnostics, Xiamen, China.
  • Xiong L; 3D Medicines, Shanghai, China.
  • Wang JJ; Department of thoracic surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Chen KN; Department of Thoracic Surgery I, Peking University Cancer Hospital and Institute, Beijing, China.
  • Zhang L; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Mao WM; Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, China.
  • Ma SL; Department of Oncology, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou, China.
  • Feng JF; Department of Chemotherapy, Jiangsu Cancer Hospital, Nanjing, China.
  • Yang XN; Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Xu L; Department of Thoracic Surgery, Jiangsu Cancer Hospital, Nanjing, China.
  • Chen G; Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Zhao J; Department of Chest Surgery, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
  • Song QB; Cancer Center of Renmin Hospital, Wuhan University, Wuhan, China.
  • Shen-Tu Y; Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
  • Qiao GB; Department of Thoracic Surgery, The General Hospital of Guangzhou Military Command, Guangzhou, China.
  • Yu D; Oncology Medicine Department, Hubei Cancer Hospital, Wuhan, China.
  • Yu SY; Cancer Center, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
  • Hu Y; Department of Internal Oncology, 301 General Hospital, Beijing, China.
  • Chen M; Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
  • Chen GY; Department of Medical Oncology, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, China.
  • Fan Y; Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, China.
  • Zhang HL; Department of Medical Oncology, Tangdu Hospital, Xian, China.
  • Liang J; Department of Medical Oncology, National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Zhu GY; Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China.
  • Cui JW; Cancer Center, The First Hospital of Jilin University, Changchun, China.
  • Yang JJ; Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
  • Zhao Q; Department of Thoracic Oncology, The First Affiliated Hospital, ZheJiang University, Hangzhou, China.
  • Zhao MF; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
ESMO Open ; 2(Suppl 1): e000174, 2017.
Article em En | MEDLINE | ID: mdl-28848676
ABSTRACT
The diagnosis and treatment of lung cancer have evolved into the era of precision medicine. Liquid biopsy, a minimally invasive approach, has emerged as a promising practice in genetic profiling and monitoring of lung cancer. Translating liquid biopsy from bench to bedside has encountered various challenges, including technique selection, protocol standardisation, data analysis and cost management. Regarding these challenges, the 2016 Chinese Lung Cancer Summit expert panel organised a trilateral forum involving oncologists, clinicians, clinical researchers, and industrial expertise on the 13th Chinese Lung Cancer Summit to formally discuss these controversies. Six consensuses were reached to guide the use of liquid biopsy and perform precision medicine in both clinic and research.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Ano de publicação: 2017 Tipo de documento: Article